Abstract
Mycobacterium avium is a human pathogen that causes infection in immunocompetent as well as immunocompromised patients. Infection is acquired both by the respiratory and gastrointestinal routes, and bacterial invasion of mucosal epithelial cells is characteristic. M. avium crosses the mucosal barrier without triggering substantial inflammatory response. Once in the intestinal submucosa or in the alveolar space M. avium infects macrophages. Intracellular bacteria block the production of cytokines involved in the host response against the infection, such as TNF-α and IL-12, and suppress antigen presentation by the macrophage. Innate response against the infection is effective to certain extent but the ability of the bacterium to remain “silent” for a period of time prevents neutrophil and NK cells from effectively controlling the establishing of the infection. CD4+ T cells as well as CD8+ T cells are activated, although only CD4+ T cells appear to be effective in inducing anti-M. avium activity in macrophages. M. avium-specific CD8+ T cells undergo apoptosis early in the infection. Therefore, the immune mechanisms of the host and bacterial strategies for survival are complex and fascinating.
Keywords: Cytokines, macrophages, immunocompetent
Current Pharmaceutical Design
Title: Role of Type I Cytokines in Host Defense Against Mycobacterium avium Infection
Volume: 9 Issue: 1
Author(s): Lia Danelishvilli and Luiz E. Bermudez
Affiliation:
Keywords: Cytokines, macrophages, immunocompetent
Abstract: Mycobacterium avium is a human pathogen that causes infection in immunocompetent as well as immunocompromised patients. Infection is acquired both by the respiratory and gastrointestinal routes, and bacterial invasion of mucosal epithelial cells is characteristic. M. avium crosses the mucosal barrier without triggering substantial inflammatory response. Once in the intestinal submucosa or in the alveolar space M. avium infects macrophages. Intracellular bacteria block the production of cytokines involved in the host response against the infection, such as TNF-α and IL-12, and suppress antigen presentation by the macrophage. Innate response against the infection is effective to certain extent but the ability of the bacterium to remain “silent” for a period of time prevents neutrophil and NK cells from effectively controlling the establishing of the infection. CD4+ T cells as well as CD8+ T cells are activated, although only CD4+ T cells appear to be effective in inducing anti-M. avium activity in macrophages. M. avium-specific CD8+ T cells undergo apoptosis early in the infection. Therefore, the immune mechanisms of the host and bacterial strategies for survival are complex and fascinating.
Export Options
About this article
Cite this article as:
Danelishvilli Lia and Bermudez E. Luiz, Role of Type I Cytokines in Host Defense Against Mycobacterium avium Infection, Current Pharmaceutical Design 2003; 9 (1) . https://dx.doi.org/10.2174/1381612033392369
DOI https://dx.doi.org/10.2174/1381612033392369 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Kidney and the Sympathetic System: A Short Review
Current Clinical Pharmacology The Role and Predictive Value of Cytokines in Atherosclerosis and Coronary Artery Disease
Current Medicinal Chemistry Immunosuppression-lipid Metabolism Interplay and Medicinal Plants in Atherosclerosis: A Review
Current Pharmaceutical Design Patents on Non-Viral Mediated Gene Delivery
Recent Patents on DNA & Gene Sequences Recent Advances in Perioperative Anesthetic Management Update in the Perioperative Support of Patients with Septic Shock and the Effect on Outcomes
Current Pharmaceutical Design Incorporation of Anti-angiogenic Therapies in the Treatment of Epithelial Ovarian Cancer: Current Perspectives and Future Directions
Current Angiogenesis (Discontinued) New Trends in Thromboxane and Prostacyclin Modulators
Current Medicinal Chemistry Acknowledgment to Contributors
Recent Patents on Inflammation & Allergy Drug Discovery A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma
Current Cancer Drug Targets Renoprotection by Direct Renin Inhibition: A Review Article and Meta-Analysis
Current Vascular Pharmacology Adrenomedullin as a Potential Therapeutic Agent for Inflammatory Bowel Disease
Current Protein & Peptide Science Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials
Current Angiogenesis (Discontinued) Cytokine-Purine Interactions in Traumatic Stress, Behavioral Depression,and Sickness
CNS & Neurological Disorders - Drug Targets The Anti-Oxidant Properties of Isothiocyanates: A Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Endothelial Function and Pathogenesis of Endothelial Dysfunction
Current Immunology Reviews (Discontinued) Structure-Activity Relationships of Low Molecular Weight Heparins Expose to the Risk of Achieving Inappropriate Targets in Patients with Renal Failure
Current Medicinal Chemistry Tissue-specific Glucocorticoid Signaling May Determine the Resistance Against Glucocorticoids in Autoimmune Diseases
Current Medicinal Chemistry The Heat Stress Response and Diabetes: More Room for Mitochondrial Implication
Current Pharmaceutical Design Immunotherapy for Myeloproliferative Neoplasms (MPN)
Current Cancer Drug Targets Structural Variety of Membrane Permeable Peptides
Current Protein & Peptide Science